On 21 September 2023:
On 31 January 2024:
So it sounds like they covered the potency assay requirement for GVHD001.
But why didn't they include any paragraph about the current inventory being "similar" or "standardised" in the 4C announcement other than the comment that it is "greater". Is it because it's not? Or do they just need to improve their communication skills?
They need to scratch where investors are feeling the most itchy.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.41 |
Change
0.620(34.6%) |
Mkt cap ! $3.084B | |||
| Open | High | Low | Value | Volume |
| $1.90 | $2.48 | $1.90 | $58.82M | 25.68M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 100915 | $2.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.41 | 99 | 1 |
View Market Depth
| Last trade - 16.12pm 18/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |